Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine
February 11, 2026Research and Development Infinitopes, Oncology
Infinitopes, a clinical stage biotechnology company specialising in oncology, has announced the receipt of an additional $15.4m in seed funding, …
Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer
February 10, 2026Angelini Pharma
Angelini Pharma, the pharmaceutical branch of Angelini Industries, has announced the appointment of Roberto Scrivo as Chief of External Affairs, …
Hongene Biotech receives Gates Foundation grant to drive mRNA vaccine production
February 10, 2026Manufacturing and Production Hongene Biotech, mRNA vaccine
Hongene Biotech, a contract development and manufacturing organisation (CDMO) and ribonucleic acid (RNA) technology provider, has announced the receipt of …
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
February 5, 2026Research and Development BMS, Scottish Medicines Consortium, colorectal cancer, oncology
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination with Yervoy (ipilimumab), by the …
AstronauTx appoints Adam Rosenberg as Chair of the Board
February 5, 2026AstronauTx, chair of the board
AstronauTx has announced the appointment of Adam Rosenberg as Chair of its Board of Directors. Rosenberg’s leadership experience includes holding …
Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer
February 4, 2026Research and Development Astellas Pharma, Scottish Medicines Consortium, Vyloy, gastric cancer, oncology
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that Vyloy (zolbetuximab), in combination with …
Angelini Pharma appoints Sergio Marullo di Condojanni as CEO
February 4, 2026Angelini Pharma, CEO
Angelini Pharma, a branch of Angelini Industries, has announced the appointment of Sergio Marullo di Condojanni as CEO. Marullo di …
QV Bioelectronics secures £4.5m in funding for brain cancer therapy development
February 3, 2026Research and Development Oncology, QV Bioelectronics, glioblastoma
QV Bioelectronics, a medtech business specialising in implants for cancer treatment, has announced that it has received £4.5m in funding …
Alvotech appoints Lisa Graver as CEO
February 3, 2026Alvotech, CEO
Alvotech has announced the appointment of Lisa Graver as CEO, following the retirement of Róbert Wessman. Wessman served as Chairman …
HonorHealth Research Institute announces first patient dosed with new stroke treatment
February 2, 2026Research and Development HonorHealth Research Institute, Neurology, ischemic stroke
HonorHealth Research Institute, a research institution collaborating with a wide range of experts to produce new treatments and devices, has …
Accord Healthcare appoints Paul Burden as Associate Vice President and Country Head UK
February 2, 2026Accord healthcare, Associate Vice President, Country Head
Accord Healthcare has announced the appointment of Paul Burden as Associate Vice President and Country Head of Accord UK. Burden …
Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases
January 30, 2026Medical Communications United Nations, WHO, healthcare access, mental health, noncommunicable diseases, primary care
The 80th United Nations General Assembly (UNGA) has adopted the political declaration to combat mental health challenges and noncommunicable diseases …
Rare diseases – spinal muscular atrophy
January 30, 2026Medical Communications gene therapy, medical communications, muscle and motor function, muscle weakness, rare diseases, sma
Spinal muscular atrophy (SMA) is a rare disease characterised by voluntary muscle weakness that can lead to difficulties in activities …
Could targeting the molecular causes of infertility finally transform IVF success rates?
January 29, 2026Medical Communications, Research and Development Biotechnology, IVF, assisted reproductive technology, fertility therapeutics, infertility
By Dr Jordan Abdi Over the past two decades, demand for IVF has risen sharply as parenthood is increasingly delayed …
Digital mental health technologies – a valuable tool in supporting people with depression and anxiety
January 29, 2026Medical Communications MHRA, NHS, NICE, Wellcome, digital technologies, medical communications, mental health
The potential benefits of digital mental health technology for managing depression, anxiety and stress, together with other forms of care, …
Barts Health NHS Trust collaborates with H.I.G. Realty on healthcare innovation building
January 29, 2026Research and Development Barts Health NHS Trust, H.I.G. Realty, health innovation
Barts Health NHS Trust and H.I.G. Realty have announced a collaboration to launch an applied healthcare innovation building in the …
Rentschler Biopharma appoints Detra Glinatsis as Head of Business Development US
January 29, 2026Head of Business Development US, Rentschler Biopharma
Rentschler Biopharma has announced the appointment of Detra Glinatsis as Head of Business Development US. Glinatsis brings more than two …
Five Facts about spinal muscular atrophy
January 28, 2026Medical Communications Five Facts, Neurology, early diagnosis, five types, gene therapy, muscle weakness, spinal muscular atrophy
1 Spinal muscular atrophy (SMA) is a genetic disease involving the loss of motor neurons in the spinal cord.1 Its …
Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases
January 28, 2026Aspaveli, European Commission, Nephrology, sobi
Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) for the treatment of two …
Everdrone appoints David Borkmann as Senior Medical Advisor
January 28, 2026Everdrone, senior medical advisor
Everdrone, a provider of autonomous drone systems for use in healthcare and emergency response, has announced the appointment of David …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
